Compare · head to head
Dongwha Pharm vs Hanall Biopharma
Dongwha Pharm ranks higher overall — 360 rank 44 vs 30.
Dongwha Pharm leads on Value (55 vs 40), Quality (51 vs 36) and Growth (57 vs 48). Hanall Biopharma leads on Safety (41 vs 29) and Sentiment (64 vs 50).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | South Korea | South Korea |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | Small | Small |
| ISIN | KR7000020008 | KR7009420001 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 44 | 30 |
| Value | 55 | 40 |
| Quality | 51 | 36 |
| Growth | 57 | 48 |
| Safety | 29 | 41 |
| Sentiment | 50 | 64 |
| Quality details | ||
| Profitability | 68 | 38 |
| Cash Truth | 34 | 34 |
Dongwha Pharm vs Kukje PharmaDongwha Pharm vs Ildong HoldingsDongwha Pharm vs Ilsung ISDongwha Pharm vs PharmGen ScienceAdd a third stock →
Full analyses: Dongwha Pharm · Hanall Biopharma
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100